Table 8 Approved novel drugs for treatment of B-lymphoid malignancies that are currently in clinical evaluation for the treatment of DLBCL

Ofatumumab (Arzerra) Second-generation anti-CD20 mAb

(↓) CD20-pro-survival signaling

GSK Genmab

B-cell chronic lymphocytic leukemia

Obinutuzumab (Gazyva/GA101) Third-generation anti-CD20 mAb

(↓) CD20-pro-survival signaling

Roche Pharmaceuticals

B-cell chronic lymphocytic leukemia

Ibrutinib (Imbruvica/PCI-32765) BTK inhibitor

(↓) BTK, BCR/NF-κB-pro-survival signaling

Pharmacyclics/Janssen Pharmaceutica

Mantle cell lymphoma B-cell chronic lymphocytic leukemia

Lenalidomide (Revlimid) Immunomodulatory drug

(↓) IRF4, BCR/NF-κB-pro-survival signaling (↑) pro-apoptotic STAT2- IFNα/β axis

Celgene

Multiple myeloma Mantle cell lymphoma

Bortezomib (Velcade) Proteasome Inhibitor

(↓) NF-κB-pro-survival signaling

Millennium Pharmaceuticals

Multiple myeloma

Carfilzomib (Kyprolis) Proteasome Inhibitor

(↓) NF-κB-pro-survival signaling

Multiple myeloma

Idelalisib (Zydelig/CAL-101, GS 1101) PI3Kδ inhibitor

(↓) PI3Kδ PI3K/AKT/mTORC1 pathway

Gilead Sciences Inc.

B-cell chronic lymphocytic leukemia Small lymphocytic lymphoma Follicular lymphoma

Dasatinib SRC kinase inhibitor

(↓) SRC family BCR/NF-κB-pro-survival signaling

Bristol-Myers Squibb

Chronic myeloid leukemia

Brentuximab vedotin

(Adcetris/SGN-35)

(↓) Tubulin

(↑) pro-apoptotic signaling

Seattle

Genetics Inc.

Hodgkin’s lymphoma

B and T-acute lymphoblastic leukemia

Antibody-drug conjugate (ADC) (anti-CD30 mAb conjugated to cytotoxin MMAE)

(MMAE is a microtubule disrupting agent)

Anaplastic lymphoma kinase-positive large B-cell lymphoma

Panobinostat (LBH589) HDAC inhibitor

(↓) HDAC, c-MYC pro-survival signaling

Novartis Pharmaceuticals

Multiple myeloma

Alemtuzumab (Campath-1H/LDP-03) Anti-CD52 mAB

(↓) CD52-pro-survival signaling

Sanofi

B-cell chronic lymphocytic leukemia